AMUNDSEN
2026
Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world
In 2,161 patients with acute myocardial infarction undergoing PCI, evolocumab started before PCI increased achievement of an LDL-C reduction of ≥50 % to below 1.4 mmol/L at 12 months compared with standard lipid-lowering care.
Résultat
Efficacité: Achievement of both a ≥50% LDL-C reduction from baseline and LDL-C <1.4 mmol/L (55 mg/dL) at 12 months; main clinical endpoint the composite of all-cause death or unplanned cardiovascular hospitalisation at 12 monthsadjusted OR 5,54 (IC à 95 % 4,50-6,82) · P < 0,001
En dessous de 1 en faveur de standard lipid-lowering care, au-dessus de 1 en faveur de evolocumab started before PCI.
- Différence absolue
- 42,0 points
- NNT
- 3
La différence absolue et le NNT sont dérivés des taux d’événements.
Également rapporté: Primary lipid endpoint met: median LDL-C at 6 weeks 16 vs 56 mg/dL. No clinical benefit: death or unplanned cardiovascular hospitalisation at 12 months 159/1087 (14.6%) vs 165/1074 (15.4%), adjusted OR 0.94 (95% CI 0.73–1.19), p=0.59
- Sous-thème
- PCSK9 inhibition in ACS
- Schéma
- International, investigator-initiated Phase IV PROBE RCT, 1:1, first evolocumab dose given before PCI, 12-month primary follow-up (clinical follow-up continuing to 2028)
- Pertinence
- Important: l’un des piliers parmi d’autres.
- Source
- Montalescot G, Ferrari E, Souteyrand G, et al. JAMA. 2026; published online 29 August.doi 10.1001/jama.2026.17302
Discussion et critique
Giving the PCSK9 antibody before the wire crosses does what the pharmacology promises: four in five reach the guideline target at a year against two in five, with a median LDL-C of 16 mg/dL at six weeks. What it does not do, over twelve months, is change death or cardiovascular readmission: an open-label trial powered for a laboratory endpoint, not for events. The lipid result is the argument for starting early; the clinical arm is the reminder that a year is short for a curve that separates late.